GeoVax Labs (GOVX) Video Presentation.
GeoVax’s COVID-19 vaccine candidates, which can induce strong antibody and T cell responses against the variants of the SARS-CoV-2 virus, also offers the possibility...
PharmaTher (PHRRF) Breaks Above Resistance.
We're now up 325% in just Under a Year. Last "big" News was Receiving a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)...
GeoVax (GOVX) Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox.
ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and...
Ardelyx (ARDX) Firmly Above Resistance.
Were not traders and we don't do technical analysis, but we could see this coming from a mile away. Next stop $9.00 and then...
Five Myths About Ketamine and Matthew Perry’s Death (Fox News).
Through the first nine months of the year, global Johnson and Johnson's Spravato Ketamine nasal-spray revenues were $483 million, an 88.8% increase over the...
Two That Doubled and Now Look Ready to Break Out.. and a Third That...
We are up 234% in Ardelyx (ARDX) $5.23 since adding it to Watch List a year ago and up 71% in Cardiol Therapeutics (CRDL)...
Tharimmune (THAR) Announces Positive Topline “Itching” Data.
Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
Phase 1 ex-US trial in chronic liver...
Psychedelic Happy Hour – Miami
Meet and Greet for Wonderland Miami Psychedelic Conference. November 10th.
Guests will enjoy cocktails, music, and plenty of networking with industry leaders in the psychedelics...
Psycheceutial Biosciences (BWVI) Listed on WeFunder!
Psycheceutical’s Psychedelic Experience, a Safer More Viable Choice in Getting Treated.
Imagine the benefits of psychedelics, without hallucinating!
Our Favorite small Psychedelic company Psycheceutical Bioscience is using...
Cybin (CYBN) Announces Unprecedented Positive Phase 2 Data After Single Dose.
Conference call to discuss CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003...